Filing Details
- Accession Number:
- 0001179110-22-000697
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-01 21:20:55
- Reporting Period:
- 2022-01-29
- Accepted Time:
- 2022-02-01 21:20:55
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1709401 | Rubius Therapeutics Inc. | RUBY | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1205703 | J Pablo Cagnoni | C/O Rubius Therapeutics, Inc. 399 Binney Street, Suite 300 Cambridge MA 02139 | Ceo And President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-01-29 | 21,250 | $0.00 | 42,250 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-02-01 | 6,730 | $6.57 | 35,520 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2022-01-29 | 21,250 | $0.00 | 21,250 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2022-01-31 | 365,000 | $0.00 | 365,000 | $6.75 |
| Common Stock | Restricted Stock Units | Acquisiton | 2022-01-31 | 100,000 | $0.00 | 100,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 63,750 | No | 4 | M | Direct | ||
| 365,000 | 2032-01-30 | No | 4 | A | Direct | |
| 100,000 | No | 4 | A | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.72, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022.
- 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.
- The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.
Billionaire Hedge Funds
